Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 2,374 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Visual Function Clear all
Terminated Phase 4 Interventional

A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma

NCT06407973
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
OMNI Surgical System, Latanoprost plus adjunctive glaucoma medication
Device · Drug
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
45 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Petaluma, California • Maryville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 22, 2026, 2:54 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Use of Apple Vision Pro as Virtual Monitor for Diagnostic and Therapeutic Procedures

NCT07797556
View directory record Official record
Conditions
Device Convenience, Device Performance, Surgeons' Rating, Ergonomics
Interventions
Not listed
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 22, 2026, 2:54 PM EDT
Completed Phase 3 Interventional Results available

Trial Comparing Atropine to Atropine Plus a Plano Lens for the Sound Eye for Amblyopia in Children 3 to <7 Years Old

NCT00315302
View directory record Official record
Conditions
Amblyopia
Interventions
Atropine, Plano Lens
Drug · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
3 Years to 6 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Fullerton, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Oct 22, 2026, 2:54 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device

NCT04918823
View directory record Official record
Conditions
Ocular Surface Disease
Interventions
Restasis
Drug
Lead sponsor
Boston Sight
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 22, 2026, 2:54 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain

NCT05265546
View directory record Official record
Conditions
Perception Disorders
Interventions
Psilocybin
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
21 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 22, 2026, 2:54 PM EDT
Completed Phase 3 Interventional Results available

A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm

NCT04503551
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
64
States / cities
Mesa, Arizona • Phoenix, Arizona • Bakersfield, California + 59 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 22, 2026, 2:54 PM EDT
Completed Phase 2 Interventional

Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma

NCT00003802
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
pyrazoloacridine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Oct 22, 2026, 2:54 PM EDT
Recruiting No phase listed Observational

iDose TR Administration in an Office-Based Surgery Setting

NCT07816692
View directory record Official record
Conditions
Open Angle Glaucoma (OAG), Ocular Hypertension (OHT)
Interventions
iDose TR (travoprost intracameral implant) 75 µg
Combination Product
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 22, 2026, 2:54 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Comparative Study of the Tomey FT-1000, and Goldmann Applanation Tonometer (GAT)

NCT07804277
View directory record Official record
Conditions
Glaucoma
Interventions
Non Contact Tonometer and Applanation Tonometer
Device
Lead sponsor
Tomey Corporation
Industry
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 2:54 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Improve the Patients' Recovery With Family- Caregivers to End Delirium

NCT05118867
View directory record Official record
Conditions
Delirium
Interventions
iPREPARED
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
60 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 22, 2026, 2:54 PM EDT
Recruiting Phase 2 Interventional

Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

NCT02521311
View directory record Official record
Conditions
Optic Neuritis
Interventions
Clemastine, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 22, 2026, 2:54 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Eye Drop Application Monitor, Pilot Study

NCT02639845
View directory record Official record
Conditions
Cataracts, Retina Surgery, Glaucoma, Any Condition That Requires Ophthalmic Drops
Interventions
Not listed
Lead sponsor
Alexander Eaton
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Dec 28, 2015 · Synced Oct 22, 2026, 2:54 PM EDT
Completed No phase listed Observational

Eye and Immunogenetic Features of Sarcoidosis

NCT00379275
View directory record Official record
Conditions
Sarcoidosis, Uveitis
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
6 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 2:54 PM EDT
Active, not recruiting Phase 3 Interventional

An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma

NCT05022901
View directory record Official record
Conditions
Metastatic Ocular Melanoma, Metastatic Uveal Melanoma
Interventions
Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS)
Combination Product
Lead sponsor
Delcath Systems Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Palo Alto, California • Tampa, Florida • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 22, 2026, 2:54 PM EDT
Completed Phase 3 Interventional Results available

A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

NCT01830140
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Bimatoprost 0.01%, Bimatoprost 0.03%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Artesia, California • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Oct 22, 2026, 2:54 PM EDT
Terminated No phase listed Observational

Imaging Lens Deposits in Exfoliation Syndrome

NCT02042703
View directory record Official record
Conditions
Exfoliation Syndrome, Primary Open Angle Glaucoma, Cataracts
Interventions
anterior segment OCT
Device
Lead sponsor
Duke University
Other
Eligibility
40 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 21, 2015 · Synced Oct 22, 2026, 2:54 PM EDT
Completed Phase 4 Interventional

Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance

NCT04412096
View directory record Official record
Conditions
Glaucoma, OHT - Ocular Hypertension
Interventions
Timolol 0.5% ophthalmic solution, Latanoprost 0.005% Ophthalmic Solution
Drug
Lead sponsor
Ohio State University
Other
Eligibility
30 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Rochester, Minnesota • Omaha, Nebraska • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 22, 2026, 2:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Closed Eye Neutrophils in Dry Eye Disease

NCT03332342
View directory record Official record
Conditions
Dry Eye, Ocular Inflammation
Interventions
Eye wash
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 17, 2019 · Synced Oct 22, 2026, 2:54 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of EGP-437 (Dexamethasone Phosphate Formulated for Ocular Iontophoresis) to Treat Dry Eye

NCT01129856
View directory record Official record
Conditions
Dry Eye
Interventions
Dexamethasone phosphate ophthalmic solution, Sodium citrate buffer solution
Drug
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Waterbury, Connecticut • Lewiston, Maine • Andover, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2011 · Synced Oct 22, 2026, 2:54 PM EDT
Terminated Phase 1 Interventional

SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy

NCT00936520
View directory record Official record
Conditions
Diabetic Macular Edema (DME), Pars Plana Vitrectomy
Interventions
SAR 1118 0.1%, SAR 1118 1.0%, SAR 1118 5.0%
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 22, 2026, 2:54 PM EDT
Terminated Not applicable Interventional

Laser Dosage in MicroPulse TransScleral CycloPhotocoagulation

NCT04709679
View directory record Official record
Conditions
Glaucoma
Interventions
MicroPulse TransScleral CycloPhotoCoagulation
Procedure
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 89 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 22, 2026, 2:54 PM EDT
Completed Not applicable Interventional Results available

Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke

NCT01662960
View directory record Official record
Conditions
Hemiparesis, Stroke
Interventions
Mirror therapy, Divider therapy
Behavioral
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
21 Years to 85 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Elkins Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 22, 2026, 2:54 PM EDT
Completed Phase 3 Interventional Results available

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)

NCT05850520
View directory record Official record
Conditions
Macular Edema Secondary to Retinal Vein Occlusion
Interventions
Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein
Drug · Diagnostic Test
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
53
States / cities
Fullerton, California • Long Beach, California • Mountain View, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 22, 2026, 2:54 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost

NCT06883123
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Simbrinza 0.2%-1% Ophthalmic Suspension, Rocklatan 0.02%-0.005% Ophthalmic Solution, Cosopt PF 2%-0.5% Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution
Drug
Lead sponsor
Prairie Eye Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 22, 2026, 2:54 PM EDT